Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.

Dimopoulos MA, Schjesvold F, Fu C, Hartley-Brown MA, Gomez C, Reece D, Mikala G, Alkharabsheh O, Parrish C, de Queiroz Crusoé E, Gálvez K, Idrobo H, White D, Gupta R, Lee C, Liu CJ, Quach H, Wang Y, Cerchione C, Forsyth C, Hungria V, Kalaskar P, Graklanov V, Ho PJ, Klaiber-Hakimi M, Kwong YL, Louzada M, Mazumder A, Miles O, Nagarajan C, Prasad SVSS, Raab MS, Varga G, von der Heyde E, Xia Z, Ochoa PA, Oriol A, Yuda J, Kuroda J, Gong J, Zhou Z, Maciag P, Yu B, Rocci A, Koo P, Katz J, Richardson PG, SUCCESSOR-2 Trial Investigators

Open source

DOI
10.1016/s0140-6736(26)01088-3
Published
2026 Jul 18
Container
Lancet (London, England)
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-26-01088-3,
  title = {Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.},
  author = {Dimopoulos MA and Schjesvold F and Fu C and Hartley-Brown MA and Gomez C and Reece D and Mikala G and Alkharabsheh O and Parrish C and de Queiroz Crusoé E and Gálvez K and Idrobo H and White D and Gupta R and Lee C and Liu CJ and Quach H and Wang Y and Cerchione C and Forsyth C and Hungria V and Kalaskar P and Graklanov V and Ho PJ and Klaiber-Hakimi M and Kwong YL and Louzada M and Mazumder A and Miles O and Nagarajan C and Prasad SVSS and Raab MS and Varga G and von der Heyde E and Xia Z and Ochoa PA and Oriol A and Yuda J and Kuroda J and Gong J and Zhou Z and Maciag P and Yu B and Rocci A and Koo P and Katz J and Richardson PG and SUCCESSOR-2 Trial Investigators},
  year = {2026},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(26)01088-3},
  url = {https://doi.org/10.1016/s0140-6736(26)01088-3}
}

RIS

TY  - JOUR
TI  - Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.
AU  - Dimopoulos MA
AU  - Schjesvold F
AU  - Fu C
AU  - Hartley-Brown MA
AU  - Gomez C
AU  - Reece D
AU  - Mikala G
AU  - Alkharabsheh O
AU  - Parrish C
AU  - de Queiroz Crusoé E
AU  - Gálvez K
AU  - Idrobo H
AU  - White D
AU  - Gupta R
AU  - Lee C
AU  - Liu CJ
AU  - Quach H
AU  - Wang Y
AU  - Cerchione C
AU  - Forsyth C
AU  - Hungria V
AU  - Kalaskar P
AU  - Graklanov V
AU  - Ho PJ
AU  - Klaiber-Hakimi M
AU  - Kwong YL
AU  - Louzada M
AU  - Mazumder A
AU  - Miles O
AU  - Nagarajan C
AU  - Prasad SVSS
AU  - Raab MS
AU  - Varga G
AU  - von der Heyde E
AU  - Xia Z
AU  - Ochoa PA
AU  - Oriol A
AU  - Yuda J
AU  - Kuroda J
AU  - Gong J
AU  - Zhou Z
AU  - Maciag P
AU  - Yu B
AU  - Rocci A
AU  - Koo P
AU  - Katz J
AU  - Richardson PG
AU  - SUCCESSOR-2 Trial Investigators
PY  - 2026
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(26)01088-3
UR  - https://doi.org/10.1016/s0140-6736(26)01088-3
ER  -

APA

MA, D., F, S., C, F., MA, H., C, G., D, R., G, M., O, A., C, P., E, D. Q. C., K, G., H, I., D, W., R, G., C, L., CJ, L., H, Q., Y, W., C, C., C, F., V, H., P, K., V, G., PJ, H., M, K., YL, K., M, L., A, M., O, M., C, N., SVSS, P., MS, R., G, V., E, V. D. H., Z, X., PA, O., A, O., J, Y., J, K., J, G., Z, Z., P, M., B, Y., A, R., P, K., J, K., PG, R., & Investigators, S. T. (2026). Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(26)01088-3

Source records